UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 30, 2012

 

NEPHROS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 (State or other jurisdiction of incorporation)

 

	001-32288		13-3971809
	(Commission File Number)		(IRS Employer ID Number)
	41 Grand Avenue, River Edge, New Jersey		07661
	(Address of principal executive offices)		(Zip Code)

 

 

Registrant's telephone number, including area code (201) 343-5202

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  

Item 8.01.  Other Events.

 

On April 30, 2012, Nephros, Inc. issued a press release announcing that it received 510(k) clearance from the Food and Drug Administration to market its Hemodiafiltration system for the treatment of chronic renal failure when used with UF controlled dialysis machines capable of producing ultrapure dialysate in accordance with current AAMI/ANSI/ISO standards in the United States.  A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

Item 9.01. Financial Statements and Exhibits.

 

	(d)           Exhibits
	Exhibit No.	Description
	99.1	Press release dated April 30, 2012.

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		Nephros, Inc.
	By:	/s/ Gerald J. Kochanski
Dated:  April 30, 2012		Gerald J. Kochanski
		Chief Financial Officer